Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Halozyme Therapeutics Inc HALO

Healthcare Biotechnology

Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. The Company’s ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, its commercially validated solution is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids, with a focus on... see more

Add To Watchlist

Recent & Breaking News (NDAQ:HALO)

Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions

PR Newswire 19 hours ago

Halozyme Confirms Proposal to Combine with Evotec for €11.00 Per Share in an All-Cash Transaction

PR Newswire 8 days ago

HALOZYME REPORTS THIRD QUARTER 2024 FINANCIAL AND OPERATING RESULTS

PR Newswire October 31, 2024

HALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE

PR Newswire October 24, 2024

Halozyme to Report Third Quarter 2024 Financial and Operating Results

PR Newswire October 23, 2024

Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx for ENHANZE®

PR Newswire October 3, 2024

Kaskela Law LLC Announces Shareholder Investigation of Halozyme Therapeutics, Inc. (HALO) and Encourages Investors to Contact the Firm

Business Wire September 17, 2024

Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO(TM) with ENHANZE® for People with Relapsing and Primary Progressive Multiple Sclerosis

PR Newswire September 13, 2024

Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza(TM) With ENHANZE® for Multiple Types of Cancer

PR Newswire September 12, 2024

Halozyme to Present at Upcoming Investor Conferences

PR Newswire August 28, 2024

HALOZYME REPORTS SECOND QUARTER 2024 FINANCIAL AND OPERATING RESULTS

PR Newswire August 6, 2024

Halozyme to Report Second Quarter 2024 Financial and Operating Results

PR Newswire July 23, 2024

Halozyme Announces Roche's OCREVUS® SC with ENHANZE® Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis

PR Newswire June 25, 2024

Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo Co-Formulated with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy

PR Newswire June 21, 2024

Halozyme Raises Full Year 2024 Financial Guidance and Updates 5-Year Financial Outlook

PR Newswire June 6, 2024

Halozyme Announces Issuance of New European Patent for ENHANZE® Drug Delivery Platform

PR Newswire June 5, 2024

Halozyme to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

PR Newswire June 4, 2024

Halozyme Announces Bristol Myers Squibb Received Updated Action Date from the U.S. Food and Drug Administration for Subcutaneous Nivolumab Co-Formulated with ENHANZE®

PR Newswire May 21, 2024

Halozyme to Participate in Upcoming Investor Conferences

PR Newswire May 8, 2024

HALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS

PR Newswire May 7, 2024